Related Experiment Video
Updated: Jun 20, 2026
08:19
Hollow Microneedle-based Sensor for Multiplexed Transdermal Electrochemical Sensing
Published on: June 1, 2012
A Dual-Bioresponsive and Programmable Microneedle Matrix as a Bioinspired Coupler for Orchestrating Diabetic Bone
Yu Wang1,2, Rui Chen1, Yu Chen1
1Department of Orthopaedic Surgery, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, P. R. China.
Advanced Materials (Deerfield Beach, Fla.)
|June 19, 2026
Summary
This study developed a novel microneedle patch to heal diabetic bone defects. The patch sequentially releases antimicrobial and anti-inflammatory agents, followed by growth factors, significantly improving bone regeneration.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Immunology
Background:
- Diabetic bone repair is hindered by infection and inflammation.
- A hostile microenvironment impedes healing in diabetic bone defects.
Purpose of the Study:
- To develop a spatiotemporally controlled therapeutic microneedle patch for diabetic bone defects.
- To address infection, inflammation, and impaired osteogenesis in diabetic bone repair.
Main Methods:
- Fabrication of a GelMA hydrogel microneedle patch (CGF/PP@MN) encapsulating Concentrated Growth Factors (CGF).
- Surface functionalization with glutathione-reactive anti-inflammatory peptide (pro-AIP) and gelatinase-cleavable antimicrobial peptide (pro-AMP).
- In vitro and in vivo evaluation in a diabetic bone defect model.
Main Results:
- Sequential, pathology-triggered release of pro-AMP, pro-AIP, and CGF.
- Effective eradication of biofilms and mitigation of inflammation.
- Promotion of M2 macrophage polarization, vascularization, and osteogenesis.
- Significant enhancement of bone regeneration and repair outcomes in vivo.
Conclusions:
- The CGF/PP@MN patch offers a combinatorial strategy for immunomodulation and regenerative repair.
- This dual-responsive system effectively addresses the challenges of diabetic bone defect healing.
- The platform demonstrates biocompatibility, bioactivity, and therapeutic potential for diabetic bone regeneration.
